Compare Summit Therapeutics Inc (SMMT) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Vanguard Ultra Short Bond ETF trades at $49.49 (market cap $10.20B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vanguard Ultra Short Bond ETF for 62 Days on average.
| SMMT | VUSB | |
|---|---|---|
Market Cap | $13.71B | $10.20B |
Volume | 6,173,057 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.38 | $50.03 |
52-Week Low | $12.43 | $49.41 |
Typical Hold Time | 16 Days | 62 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
VUSB trades at $49.49, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend, while recent news highlights short-term bond ETF appeal amid potential Fed rate hikes. The company has announced upcoming dividends, with three distributions scheduled for H2-2026.
The outlook remains cautious due to bearish technicals and interest rate sensitivity. Opportunities include dividend income, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term stability against macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
